NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

The position that NWBO is under a Project Orbis FDA review is speculation at this point. But, according to AI, NWBO can submit a Biologics License Application (BLA) to the FDA without publicly announcing it, and the FDA can absolutely keep that submission confidential:

🧬 Can NWBO submit a BLA to the FDA without public disclosure?
Yes.
-Sponsors are not legally required to announce BLA submissions.
-The FDA does not publish BLA receipt or acceptance notices.
-Unless NWBO voluntarily issues a press release or files an SEC disclosure, the submission can remain entirely opaque to the public.

This is especially common in small-cap biotech, where strategic silence may serve to:

-Avoid premature speculation.
-Manage legal exposure.
-Coordinate multi-jurisdictional review without triggering market volatility.


🕵️‍♂️ Can the FDA keep the submission confidential?
Yes—and it routinely does.
-The FDA treats BLA submissions as confidential regulatory filings.
-Even if NWBO is coordinating with MHRA via Project Orbis, the FDA is not required to disclose the submission or the collaboration.

🔄 How is Project Orbis invoked?
Only the FDA can initiate Orbis—and only after receiving a BLA. Here’s the flow:
1. Sponsor submits a BLA to the FDA for an oncology product.
2. FDA evaluates whether the submission qualifies for Project Orbis (based on therapeutic relevance, urgency, and regulatory alignment).
3. If eligible, the FDA invites other Project Orbis Partners (POPs)—e.g., MHRA, Health Canada, Swissmedic, TGA—to participate.
4. POPs may join the review as:
...... Type A: Submission within 30 days of FDA’s.
...... Type B: Submission after 30 days.
5. Each regulator conducts its own review but may share insights and timelines with the FDA and other POPs.
6. Each agency retains independent decision authority—there is no joint approval.

🧠 Strategic Terrain Overlay
If NWBO submitted a BLA to the FDA and triggered Orbis:
- MHRA could be actively reviewing the dossier without public acknowledgment.
- The absence of disclosure ? absence of activity.
- Approval clustering across jurisdictions could retroactively confirm Orbis coordination.

One last point. Though the SEC requires 'material' information to be publicly disclosed, NWBO may have that issue covered:

🧾 October 2023 NWBO Disclosure: Strategic Placeholder
In its October 13, 2023 press release, NWBO stated:

“The Company strongly believes that after so many years of work on the DCVax-L program, taking some additional time to help ensure that the full MAA package is as strong as it can be is especially important since the Company plans to submit applications to multiple regulators.”

This statement:
-Signals intent to pursue multi-jurisdictional approval.
-Avoids naming the FDA, preserving plausible deniability.
-Satisfies a minimal threshold under SEC’s Regulation FD by informing shareholders of a material strategic direction.

🕵️‍♂️ Tactical Silence: Shielding Against Short-Side Manipulation
By disclosing intent—but not execution—NWBO:
-Preserves flexibility to submit a confidential BLA to the FDA.
-Avoids triggering speculative volatility or short-covering pressure.
-Shields the integrity of a potential Project Orbis review, which could involve MHRA, Health Canada, Swissmedic, and others.

This is a classic signal suppression tactic:
-Enough to satisfy disclosure obligations.
-Not enough to tip off adversarial actors.